

therapy, with a lower risk of hypoglycemia and without affecting weight versus sulfonylurea and metformin combination.

PDB24

RECOMBINANT GROWTH HORMONE THERAPY IN CHILDREN WITH GH DEFICIENCY: FIRST INTERVENTIONAL STUDY IN ARMENIA

Markosyan R, Perikhanyan A

Yerevan State Medical University, Yerevan, Armenia

OBJECTIVES: The purpose of this study was to evaluate the effectiveness and safety of treatment with recombinant growth hormone (RGH) in children with GH deficiency. **METHODS:** This was an interventional study with 6 and 12 months follow-up. Treatment was received by 15 children. The patients were receiving the RGH in 0.033 mg/kg (0.1 Unit/kg) at the same time each day (9–10 pm) for period of 1 year. The effectiveness of treatment was evaluated based on change in growing speed, growth SDS and bone age maturation. **RESULTS:** The mean age of children was 9.5±3.6 years. In the given sample 6 children had MHPD, other 9 children had IGHD. There was a great improvement in absolute growth at 6 and 12 months period of treatment (p<0.001; p<0.001). The same was found for growth SDS (p<0.001; p<0.001). Effectiveness of RGH therapy on bone age maturation also showed great improvement (p<0.001; p<0.001). The level of IGF-1 was increased (p<0.001; p<0.001); at 12 months the level of IGF-1 reached to 248.72±70.7 ng/mL and remained consistently high. The same improvement was in IGF-pb3 levels (p<0.001; p<0.001). The lipidemic analysis showed that the blood cholesterol levels were from 3.21 to 12.39 mmol/L (norm 5.68±1.55 mmol/L) and the level of LDL - 1.3 to 10.86 mmol/L (norm 3.83±1.44 mmol/L). During the treatment period we observed the significant improvement in cholesterol levels (p<0.001; p<0.001). High density lipoprotein and triglyceride levels did not change significantly (p. 0.05). **CONCLUSIONS:** It can be concluded that the treatment with RGH in patient with GH deficiency is beneficial as it normalized the levels of cholesterol and LDL. During the treatment there were no any changes in indicators of kidney's function, indicators of liver's function as well as the indicators of carbohydrate metabolism.

PDB25

EFFECTIVENESS, SAFETY AND PATIENTS' SUBJECTIVE FEELINGS OF INSULIN PEN-NEEDLE: A SYSTEMATIC REVIEW

Sun L, Sun J, Chen B, Sun S, Wang R, Ren X

Shenyang Pharmaceutical University, Shenyang, China

OBJECTIVES: To compare the differences of effectiveness, safety and patients' subjective feelings for using different lengths of insulin pen-needle in diabetic patients. **METHODS:** A retrospective analysis of relevant publications that were identified via electronic searches of databases using multiple search terms related to insulin pen-needle. **RESULTS:** Totally, 21 literatures were included. Firstly, for the effectiveness, 85.71% of the studies suggested that there was no difference between longer and shorter needle in controlling HbA1c, 14.29% thought the shorter needle was better than the longer. No changes were observed with respect to fructosamine, glycated albumin and body mass index. Secondly, about the safety, all of the studies proved that the shorter needle was better in intramuscular injections, adverse device effects, subcutaneous lipodystrophy and barb phenomenon. 33.33% reported less hypoglycemic events, bleeding, bruising and needle bending with the shorter needle, the others showed no difference. All of the studies considered the shorter needle was undifferentiated with the longer in the needle break, hyperglycemia and lipohypertrophy. 6.25% have pointed out that the shorter needle was better than the longer in leakage, while 81.25% showed no difference in the length. Thirdly, in terms of subjective feelings, for convenience and acceptance, all studies agreed that shorter needle was superior to the longer. For fear and pain, half of studies suggested that shorter needle was superior to the longer one; the other half thought that there was no difference. In all the studies, 69.23% suggested patients prefer the shorter, 23.08% suggested the patients not prefer a particular needle length. **CONCLUSIONS:** Overall, the effectiveness of insulin pens with longer and shorter needle are comparable in treating diabetes, but the shorter needle is little better in parts of the safety indexes. As for patients' subjective feeling, our findings show that patients are generally willing to accept shorter needle.

PDB26

ECONOMIC IMPACT OF COMBINING METFORMIN WITH DIPEPTIDYL PEPTIDASE INHIBITORS IN DIABETIC PATIENTS WITH RENAL FAILURE

Sicras-Mainar A¹, Navarro-Artieda R²

¹Badalona Serveis Assistencials, Badalona, Barcelona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain

OBJECTIVES: To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal failure (RF) in routine clinical practice. **METHODS:** An observational, retrospective study was performed. Patients aged ≥ 30 years treated with metformin who initiated a second oral antidiabetic treatment in 2008–2009 were included. Two groups of patients were analysed: a) metformin + DPP-4 inhibitors and b) other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated haemoglobin <7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for two years. **RESULTS:** We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin + DPP-4 inhibitors and 260 patients received metformin + other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%) and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (p<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), p = 0.001. **CONCLUSIONS:** Despite the limitations of the study, patients with renal failure treated with DPP-4 inhibitors had better metabolic control, lower rates of hypoglycaemia, and lower health costs for the Spanish national health system.

PDB27

USES OF ELECTRONIC PATIENT INFORMATION SYSTEMS AND NATIONAL REGISTERS – IMPLEMENTATION OF THE CLINICAL PRACTICE GUIDELINE AND EVALUATION OF COSTS AND USE OF RESOURCES IN PATIENTS WITH INCIDENT TYPE 2 DIABETES IN FINLAND

Prami T¹, Sulamaa A², Sipilä R³, Linna M⁴, Hahl J⁵, Miettinen T⁵, Leppä E⁶, Haukka J¹, Tuomilehto J⁷, Enlund H⁸, Niskanen L⁸, Korhonen P¹

¹EPID Research, Espoo, Finland, ²Pharma Industry Finland, Helsinki, Finland, ³Finnish Medical Society Duodecim, Helsinki, Finland, ⁴Aalto University, HEMA Institute, Espoo, Finland, ⁵AT Medical Affairs Consulting, Espoo, Finland, ⁶Pharmaceutical Information Centre, Helsinki, Finland, ⁷University of Helsinki, Helsinki, Finland, ⁸Finnish Medicines Agency Fimea, Helsinki, Finland

OBJECTIVES: Effective management of diabetes is the cornerstone for prevention of diabetic complications. However, how well the Finnish Current Care guideline for diabetes is implemented in practice is unknown. Combining local and nationwide patient registers provide a valuable resource for evaluating risks, benefits and costs. The purpose of this study was to identify how the Finnish electronic patient information systems and national registers can be used to explore the treatment for patients with incident type 2 diabetes. **METHODS:** Selected primary and specialty care organizations representing different geographical areas and patient information system providers were invited to participate in the study. Study permits were obtained from several local and nationwide register holders. The study protocol was reviewed by the Ethical Review Board of Hospital District of Helsinki and Uusimaa. **RESULTS:** Register linkage is accomplished using unique personal identification numbers. We collect nationwide data on prescriptions, hospital and primary care, reimbursed dental care, and the causes of death. Cost data are based on hospital benchmarking database, sickness allowances and rehabilitations. We use local registers as a source of information on diagnoses, medical procedures, prescriptions and contact types. High quality laboratory data are also included from several local providers. **CONCLUSIONS:** Register linkages enable longitudinal follow-up of patients for research purposes in Finland. In our study a unique combined register database of diabetic patient cohort is created that improves the evaluation of prognosis and care of diabetic patients. This is a promising and versatile source for research in pharmacoepidemiology.

PDB28

EPIDEMIOLOGY AND UNMET MEDICAL NEED IN DIABETES MELLITUS TYPE 2 IN GERMANY –RESULTS OF A LITERATURE SEARCH

Greiner RA¹, Paulus G¹, Driedger J¹, Schröder C¹, Timtschenko V¹, Batscheider A¹, Eheberg D², Vosgerau S¹

¹IMS Health, Munich, Germany, ²IMS HEALTH, Munich, Germany

OBJECTIVES: Diabetes mellitus Type 2 (T2DM) is a metabolic disease characterized by hyperglycemia with a high risk-potential of microvascular and macrovascular complications. In addition to glycemic control important therapy targets are the prevention of hypoglycemia and weight gain as well as blood pressure control due to national guidelines (German Medical Association 2013). To describe the current state of T2DM epidemiology and therapeutic needs in Germany which is mandatory when submitting AMNOG dossiers. **METHODS:** To describe epidemiology of diabetes a targeted literature research was conducted in PubMed in 2014 using the search terms (epidemiology OR incidence OR prevalence). To identify relevant comorbidity information the following terms were used (metabolic syndrome OR glycemic control OR hypoglycemia OR obesity OR blood pressure) and combined with AND diabetes AND Germany. PubMed research was supplemented by additional searches in guidelines in German/English. **RESULTS:** The screening of the epidemiologic results identified nine relevant publications: two specified a T2DM-prevalence of 15.3% and 14.7% (Wittchen et al 2007, Huppertz et al 2009) and two studies estimated a T2DM incidence of 15.8 per 1000 patient years (KORA, MONICA). Treatment prevalence increased from 5.9% in 1998 to 8.9% in 2007 related to the total population (Hauner 2013). Arterial hypertension was the most frequent comorbidity (83%) of T2DM (Hagen et al. 2010). In 2010, a disease management program in North Rhine showed that only 15% of participants with T2DM achieved a BMI <25 (Hagen et al. 2010). Long-term trials investigating the efficacy of antidiabetics on the prevention of macrovascular complications are limited (Drug Commission of German Medical Association 2009; Matthaei et al. 2009). **CONCLUSIONS:** While treatment prevalence is increasing and glycemic control seems to be sufficiently achieved a substantial unmet medical need is identified for antidiabetics with a significant effect on weight reduction and blood pressure control in patients with T2DM in Germany.

PDB29

PROGRESSION OF PHYSIOLOGICAL PARAMETERS OVER TIME IN TYPE 1 DIABETES MELLITUS PATIENTS IN FRANCE

Beaudet A, Ong RC

IMS Health, Basel, Switzerland

OBJECTIVES: The objective of this study was to understand the progression over time of physiological parameters, including HbA1c, body mass index (BMI), systolic blood pressure (SBP), total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, in type 1 diabetes mellitus (T1DM) patients to inform disease modeling. **METHODS:** This was a cross-sectional analysis of T1DM patients based on the IMS LifeLink Diabetes Cohort in France, which prospectively collects clinical, biological and treatment information from general practitioners. Patient age, gender, year of diagnosis, BMI, HbA1c, cardiovascular risk factors, renal function and lab test results were collected at baseline and subsequent visits. Data were analyzed using R Studio. T1DM patients who visited their general physician between May 2011 and May 2014 and have received at least one insulin prescription were included in the analysis. **RESULTS:** A cohort of 605 T1DM patients was included in this analysis. Forty-three percent of patients were male. Average patient age at first visit was 58 years of age. Mean HbA1c was 7.8%, mean SBP was 132 mmHg, and mean BMI was 27.6 kg/m². Linear regression showed that BMI increased by 0.092 kg/m² (p<0.001) for each additional year of age. SBP was projected to increase by 0.248 mmHg (p<0.001) per additional year of age. LDL-cholesterol decreased by